Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370693 · ClinicalTrials.gov registry record · Phase 2
Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis
A Phase 2 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT02370693 is a Phase 2 study that has completed, run by Northwestern University. The registered enrollment target is 9 participants.
The verdict
NCT02370693, a Phase 2 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
Interventions
- DRUG Placebo
- DRUG Bortezomib
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-03 |
| Est. Completion | 2020-01-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02370693
The ClinicalTrials.gov registry entry for NCT02370693 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02370693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02370693 about?
NCT02370693 is a clinical study titled "Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis". The purpose of this study is to look at whether bortezomib, mycophenolate or the combination of both is better to treat scarring of the lung caused by Systemic Sclerosis.
What is the current status of trial NCT02370693?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2016-03. Estimated completion is 2020-01-01.
What interventions are being tested in trial NCT02370693?
The interventions under investigation include: Placebo (DRUG), Bortezomib (DRUG), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT02370693?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.